Work

Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8021

Authors: Paul K. Paik, Alexander E. Drilon, Helena Alexandra Yu, Lee M. Krug, Natasha Rekhtman, Laetitia Borsu, Michelle S. Ginsberg, Michael F. Berger, Marc Ladanyi, Charles M. Rudin

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603086641

Cites:

Cited by: 8

Related to: 10